» Articles » PMID: 35930537

FXR Deficiency in Hepatocytes Disrupts the Bile Acid Homeostasis and Inhibits Autophagy to Promote Liver Injury in Schistosoma Japonicum-infected Mice

Overview
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Schistosomiasis, with 250 million people affected, is characterized by its serious hepatic inflammatory response and fibrosis formation, which could lead to dangerous complications, such as portal hypertension, splenomegaly and even ascites. But until now, the pathogenesis of schistosomiasis remains largely unknown. Farnesoid X Receptor (FXR), a bile acid-activated nuclear transcription factor mainly expresses in hepatocytes in the liver, can regulate liver diseases by controlling bile acid metabolism.

Methodology/principal Findings: In this study, we found that the expression of FXR was decreased in the liver of infected mice as shown by western blot and RT-qPCR assays. Furthermore, hepatocyte-specific FXR-deficient mice (FXRflox/floxAlbCre, FXR-HKO) were generated and infected with ~16 cercariae of S. japonicum for five weeks. We found that FXR deficiency in hepatocytes promoted the progression of liver injury, aggravated weight loss and death caused by infection, and promoted inflammatory cytokines production, such as IL-6, IL-1β, TNF-α, IL-4, IL-10, and IL-13. Surprisingly, hepatic granulomas and fibrosis were not affected. In addition, using UPLC-MS/MS spectrometry, it was found that S. japonicum infection resulted in elevated bile acids in the liver of mice, which was more obvious in FXR-deficient mice. Meanwhile, autophagy was induced in littermate control mice due to the infection, but it was significantly decreased in FXR-HKO mice.

Conclusions/significance: All these findings suggest that FXR deficiency in hepatocytes disrupts bile acid homeostasis and inhibits autophagy, which may aggravate the damages of hepatocytes caused by S. japonicum infection. It highlights that FXR in hepatocytes plays a regulatory role in the progression of schistosomiasis.

Citing Articles

Metabolomic analysis of the intrinsic resistance mechanisms of Microtus fortis against Schistosoma japonicum infection.

He T, Zhang D, Wen Y, Liu Q, Zhou J, Zhi W Sci Rep. 2025; 15(1):7147.

PMID: 40021829 PMC: 11871335. DOI: 10.1038/s41598-025-91164-z.


Metabolomics analysis of patients with Schistosoma japonicum infection based on UPLC-MS method.

Li J, Jiang J, Zhu Y, Zhang Y, Zhu J, Ming Y Parasit Vectors. 2024; 17(1):350.

PMID: 39164750 PMC: 11334362. DOI: 10.1186/s13071-024-06429-9.


Gut microbiota and immune profiling of microbiota-humanised versus wildtype mouse models of hepatointestinal schistosomiasis.

Stark K, Rinaldi G, Costain A, Clare S, Tolley C, Almeida A Anim Microbiome. 2024; 6(1):36.

PMID: 38918824 PMC: 11201864. DOI: 10.1186/s42523-024-00318-3.


Autophagy in hepatic progenitor cells modulates exosomal miRNAs to inhibit liver fibrosis in schistosomiasis.

Yuan Y, Li J, Lu X, Chen M, Liang H, Chen X Front Med. 2024; 18(3):538-557.

PMID: 38769281 DOI: 10.1007/s11684-024-1079-1.


Inhibiting Liver Autophagy and Promoting Hepatocyte Apoptosis by Infection.

Yu Z, Jiang T, Xu F, Zhang J, Hu Y, Cao J Trop Med Infect Dis. 2024; 9(2).

PMID: 38393131 PMC: 10892706. DOI: 10.3390/tropicalmed9020042.


References
1.
Li Z, Kruijt J, van der Sluis R, Van Berkel T, Hoekstra M . Nuclear receptor atlas of female mouse liver parenchymal, endothelial, and Kupffer cells. Physiol Genomics. 2013; 45(7):268-75. DOI: 10.1152/physiolgenomics.00151.2012. View

2.
Qian H, Chao X, Williams J, Fulte S, Li T, Yang L . Autophagy in liver diseases: A review. Mol Aspects Med. 2021; 82:100973. PMC: 9585624. DOI: 10.1016/j.mam.2021.100973. View

3.
Fiorucci S, Biagioli M, Zampella A, Distrutti E . Bile Acids Activated Receptors Regulate Innate Immunity. Front Immunol. 2018; 9:1853. PMC: 6099188. DOI: 10.3389/fimmu.2018.01853. View

4.
Saha S, Panigrahi D, Patil S, Bhutia S . Autophagy in health and disease: A comprehensive review. Biomed Pharmacother. 2018; 104:485-495. DOI: 10.1016/j.biopha.2018.05.007. View

5.
Trauner M, Fuchs C . Novel therapeutic targets for cholestatic and fatty liver disease. Gut. 2021; 71(1):194-209. PMC: 8666813. DOI: 10.1136/gutjnl-2021-324305. View